External genital warts: Diagnosis, treatment, and prevention

Clinical Infectious Diseases

Volumn 35, Issue , 2002, Pages S210-S224

  Wiley, D J ^a   Douglas, John ^e   Beutner, Karl ^b,d   Cox, Tom ^c   Fife, Kenneth ^f   Moscicki, Anna Barbara ^b   Fukumoto, Lynne ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d Solano Clinical Research   (United States)

^e NONE   (United States)

^f INDIANA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIDOFOVIR; DICHLOROACETIC ACID; FLUOROURACIL; IMIQUIMOD; PODOPHYLLIN; PODOPHYLLOTOXIN; RECOMBINANT INTERFERON; TRICHLOROACETIC ACID;

ARTICLE; BIOPSY; BLEEDING; CESAREAN SECTION; CONDOM; CONDYLOMA; CRYOTHERAPY; DYSPAREUNIA; ERYTHEMA; FEMALE; HUMAN; INFLAMMATION; INSOMNIA; MALE; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PRURITUS; RECURRENT DISEASE; SEXUALLY TRANSMITTED DISEASE; VERTICAL TRANSMISSION; WART VIRUS;

AMINOQUINOLINES; ANTINEOPLASTIC AGENTS; CONDYLOMATA ACUMINATA; CRYOTHERAPY; EDUCATION; ELECTROSURGERY; FEMALE; FLOXURIDINE; HUMANS; INTERFERONS; LASER SURGERY; MALE; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PODOPHYLLIN; PODOPHYLLOTOXIN; TUMOR VIRUS INFECTIONS;

EID: 0037108603     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/342109     Document Type: Article

References (234)

1. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189:12-9.
2. Bosch FX, Manos MM, Munoz N, et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst 1995; 87:796-802.
3. Gross G, Pfister H, Hagedorn M, Gissmann L. Correlation between human papillomavirus (HPV) type and histology of warts. J Invest Dermatol 1982; 78:160-4.
4. Stubenrauch F, Laimins LA. Human papillomavirus life cycle: active and latent phases. Semin Cancer Biol 1999; 9:379-86.
5. Los Alamos National Laboratory, Bioscience Division, The Regents of the University of California. PV types and hosts. (University of California under contract W-7405-ENG-36 with the United States Department of Energy, 1998-2001.) 2001. Available at: http://www .stdgen.lanl.gov/stdgen/virus/cgi-bin/hpv_organisms.cgi?dbname= hpv. Accessed 30 June 2001.
6. de Villiers EM. Human papillomavirus: introduction. Semin Cancer Biol 1999; 9:377.
7. Gissmann L, zur Hausen H. Partial characterization of viral DNA from human genital warts (condylomata acuminata). Int J Cancer 1980; 25:605-9.
8. Los Alamos National Laboratory, Bioscience Division, The Regents of the University of California. PV types and hosts: HPV6. University of California under contract W-7405-ENG-36 with the United States Department of Energy, 1998-2001. Available at: http://www.stdgen.lanl.gov/stdgen/virus/cgi-bin/types_lookup.cgi? dbname=hpvg&type g=g6&organism=Human%20papillomavirus. Accessed 14 February 2000.
9. Gissmann L, deVilliers EM, zur Hausen H. Analysis of human genital warts (condylomata acuminata) and other genital tumors for human papillomavirus type 6 DNA. Int J Cancer 1982; 29:143-6.
10. Gissmann L, Wolnik L, Ikenberg H, Koldovsky U, Schnurch HG, zur Hausen H. Human papillomavirus types 6 and 11 DNA sequences in genital and laryngeal papillomas and in some cervical cancers. Proc Natl Acad Sci USA 1983; 80:560-3.
11. Gissmann L. Human papillomavirus DNA in genital tumours. IARC Sci Pub 1984; 63:405-11.
12. Gissmann L, Boshart M, Durst M, Ikenberg H, Wagner D, zur Hausen H. Presence of human papillomavirus in genital tumors. J Invest Dermatol 1984; 83(1 Suppl):26s-8s.
13. Eron LJ, Alder MB, JM OR, Rittweger K, DePamphilis J, Pizzuti DJ. Recurrence of condylomata acuminata following cryotherapy is not prevented by systemically administered interferon. Genitourin Med 1993; 69:91-3.
14. Armstrong DK, Maw RD, Dinsmore WW, et al. A randomised, double-blind, parallel group study to compare subcutaneous interferon alpha-2a plus podophyllin with placebo plus podophyllin in the treatment of primary condylomata acuminata. Genitourin Med 1994; 70:389-93.
15. Armstrong DK, Maw RD, Dinsmore WW, et al. Combined therapy trial with interferon alpha-2a and ablative therapy in the treatment of anogenital warts. Genitourin Med 1996; 72:103-7.
16. Bonnez W, Oakes D, Bailey-Farchione A, et al. A randomized, double-blind, placebo-controlled trial of systemically administered interferonalpha, -beta, or -gamma in combination with cryotherapy for the treatment of condyloma acuminatum. J Infect Dis 1995; 171:1081-9.
17. Condylomata International Collaborative Study Group. A comparison of interferon alfa-2a and podophyllin in the treatment of primary condylomata acuminata. Genitourin Med 1991; 67:394-9.
18. Condylomata International Collaborative Study Group. Recurrent condylomata acuminata treated with recombinant interferon alfa-2a. A multicenter double-blind placebo-controlled clinical trial. Condylomata International Collaborative Study Group. JAMA 1991; 265:2684-7.
19. Condylomata International Collaborative Study Group. Recurrent condylomata acuminata treated with recombinant interferon alpha-2a. A multicenter double-blind placebo-controlled clinical trial. Acta Derm Venereol 1993; 73:223-6.
20. Condylomata International Collaborative Study Group. Randomized placebo-controlled double-blind combined therapy with laser surgery and systemic interferon-alpha 2a in the treatment of anogenital condylomata acuminatum. J Infect Dis 1993; 167:824-9.
21. Kirby PK, Kiviat N, Beckman A, Wells D, Sherwin S, Corey L. Tolerance and efficacy of recombinant human interferon gamma in the treatment of refractory genital warts. Am J Med 1988; 85:183-8.
22. Reichman RC, Micha JP, Weck PK, et al. Interferon alpha-n1 (Wellferon) for refractory genital warts: efficacy and tolerance of low dose systemic therapy. Antiviral Res 1988; 10:41-57.
23. Syed TA, Cheema KM, Khayyami M, Ahmad SA, Ahmad SH, Ahmad S. Human leukocyte interferon-alpha versus podophyllotoxin in cream for the treatment of genital warts in males. A placebo-controlled, double-blind, comparative study. Dermatology 1995; 191:129-32.
24. Greenberg MD, Rutledge LH, Reid R, Berman NR, Precop SL, Elswick RK Jr. A double-blind, randomized trial of 0.5% podofilox and placebo for the treatment of genital warts in women. Obstet Gynecol 1991; 77:735-9.
25. Syed TA, Lundin S. Topical treatment of penile condylomata acuminata with podophyllotoxin 0.3% solution, 0.3% cream and 0.15% cream. Dermatology 1993; 187:30-3.
26. Beutner KR, Wiley DJ, Douglas JM, et al. Genital warts and their treatment. Clin Infect Dis 1999; 28(Suppl 1):S37-56.
27. Evander M, Frazer IH, Payne E, Qi YM, Hengst K, McMillan NA. Identification of the alpha6 integrin as a candidate receptor for papillomaviruses. J Virol 1997; 71:2449-56.
28. McMillan NA, Payne E, Frazer IH, Evander M. Expression of the alpha6 integrin confers papillomavirus binding upon receptor-negative B-cells. Virology 1999; 261:271-9.
29. Payne E, Bowles MR, Don A, Hancock JF, McMillan NA. Human papillomavirus type 6b virus-like particles are able to activate the RasMAP kinase pathway and induce cell proliferation. J Virol 2001; 75:4150-7.
30. Joyce JG, Tung JS, Przysiecki CT, et al. The L1 major capsid protein of human papillomavirus type 11 recombinant virus-like particles interacts with heparin and cell-surface glycosaminoglycans on human keratinocytes. J Biol Chem 1999; 274:5810-22.
31. de Villiers EM, Gissmann L, zur Hausen H. Molecular cloning of viral DNA from human genital warts. J Virol 1981; 40:932-5.
32. Durst M, Croce CM, Gissmann L, Schwarz E, Huebner K. Papillomavirus sequences integrate near cellular oncogenes in some cervical carcinomas. Proc Natl Acad Sci USA 1987; 84:1070-4.
33. Lorincz AT, Reid R, Jenson AB, Greenberg MD, Lancaster W, Kurman RJ. Human papillomavirus infection of the cervix: relative risk associations of 15 common anogenital types. Obstet Gynecol 1992; 79:328-37.
34. Koutsky LA, Holmes KK, Critchlow CW, et al. A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection. N Engl J Med 1992; 327:1272-8.
35. Hildesheim A, Herrero R, Castle PE, et al. HPV co-factors related to the development of cervical cancer: results from a population-based study in Costa Rica. Br J Cancer 2001; 84:1219-26.
36. Hildesheim A, Schiffman M, Bromley C, et al. Human papillomavirus type 16 variants and risk of cervical cancer. J Natl Cancer Inst 2001; 93:315-8.
37. Yamada T, Manos MM, Peto J, et al. Human papillomavirus type 16 sequence variation in cervical cancers: a worldwide perspective. J Virol 1997; 71:2463-72.
38. Carter JJ, Madeleine MM, Shera K, et al. Human papillomavirus 16 and 18 L1 serology compared across anogenital cancer sites. Cancer Res 2001; 61:1934-40.
39. Ho GY, Burk RD, Fleming I, Klein RS. Risk of genital human papillomavirus infection in women with human immunodeficiency virus-induced immunosuppression. Int J Cancer 1994; 56:788-92.
40. Critchlow CW, Holmes KK, Wood R, et al. Association of human immunodeficiency virus and anal human papillomavirus infection among homosexual men. Arch Intern Med 1992; 152:1673-6.
41. Kiviat N, Rompalo A, Bowden R, et al. Anal human papillomavirus infection among human immunodeficiency virus-seropositive and -seronegative men. J Infect Dis 1990; 162:358-61.
42. Tan W, Felber BK, Zolotukhin AS, Pavlakis GN, Schwartz S. Efficient expression of the human papillomavirus type 16 L1 protein in epithelial cells by using Rev and the Rev-responsive element of human immunodeficiency virus or the cis-acting transactivation element of simian retrovirus type 1. J Virol 1995; 69:5607-20.
43. Volter C, He Y, Delius H, et al. Novel HPV types present in oral papillomatous lesions from patients with HIV infection. Int J Cancer 1996; 66:453-6.
44. Arany I, Evans T, Tyring SK. Tissue specific HPV expression and downregulation of local immune responses in condylomas from HIV seropositive individuals. Sex Transm Infect 1998; 74:349-53.
45. Forslund O, Nordin P, Andersson K, Stenquist B, Hansson BG. DNA analysis indicates patient-specific human papillomavirus type 16 strains in Bowen's disease on fingers and in archival samples from genital dysplasia. Br J Dermatol 1997; 136:678-82.
46. Koutsky L. Epidemiology of genital human papillomavirus infection. Am J Med 1997; 102:3-8.
47. Koutsky LA, Galloway DA, Holmes KK. Epidemiology of genital human papillomavirus infection. Epidemiol Rev 1988; 10:122-63.
48. Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998; 338:423-8.
49. Herrero R, Hildesheim A, Bratti C, et al. Population-based study of human papillomavirus infection and cervical neoplasia in rural Costa Rica. J Natl Cancer Inst 2000; 92:464-74.
50. Franco EL, Rohan TE, Villa LL. Epidemiologic evidence and human papillomavirus infection as a necessary cause of cervical cancer. J Natl Cancer Inst 1999; 91:506-11.
51. Van Doornum GJ, Prins M, Juffermans LH, et al. Regional distribution and incidence of human papillomavirus infections among heterosexual men and women with multiple sexual partners: a prospective study. Genitourin Med 1994; 70:240-6.
52. Wheeler CM, Parmenter CA, Hunt WC, et al. Determinants of genital human papillomavirus infection among cytologically normal women attending the University of New Mexico student health center. Sex Transm Dis 1993; 20:286-9.
53. Jamison JH, Kaplan DW, Hamman R, Eagar R, Beach R, Douglas JM Jr. Spectrum of genital human papillomavirus infection in a female adolescent population. Sex Transm Dis 1995; 22:236-43.
54. Kiviat NB, Koutsky LA, Paavonen JA, et al. Prevalence of genital papillomavirus infection among women attending a college student health clinic or a sexually transmitted disease clinic. J Infect Dis 1989; 159:293-302.
55. Baken LA, Koutsky LA, Kuypers J, et al. Genital human papillomavirus infection among male and female sex partners: prevalence and type-specific concordance. J Infect Dis 1995; 171:429-32.
56. Evander M, Edlund K, Gustafsson A, et al. Human papillomavirus infection is transient in young women: a population-based cohort study. J Infect Dis 1995; 171:1026-30.
57. Carter JJ, Koutsky LA, Wipf GC, et al. The natural history of human papillomavirus type 16 capsid antibodies among a cohort of university women. J Infect Dis 1996; 174:927-36.
58. Moscicki AB, Shiboski S, Broering J, et al. The natural history of human papillomavirus infection as measured by repeated DNA testing in adolescent and young women. J Pediatr 1998; 132:277-84.
59. Hong K, Greer CE, Ketter N, Van Nest G, Paliard X. Isolation and characterization of human papillomavirus type 6-specific T cells infiltrating genital warts. J Virol 1997; 71:6427-32.
60. Handley JM, Maw RD, Horner T, Lawther H, Walsh M, Dinsmore WW. A placebo controlled observer blind immunocytochemical and histologic study of epithelium adjacent to anogenital warts in patients treated with systemic interferon alpha in combination with cryotherapy or cryotherapy alone. Genitourin Med 1992; 68:100-5.
61. Tagami H, Oku T, Iwatsuki K. Primary tissue culture of spontaneously regressing flat warts. In vitro attack by mononuclear cells against wart-derived epidermal cells. Cancer 1985;55:2437-41.
62. Beutner K, Wiley D. Recurrent external genital warts: a literature review. Papillomavirus Report 1997; 8:69-74.
63. Beutner KR, Richwald GA, Wiley DJ, Reitano MV. External genital warts: report of the American Medical Association Consensus Conference. AMA Expert Panel on External Genital Warts. Clin Infect Dis 1998; 27:796-806.
64. Blohme I, Brynger H. Malignant disease in renal transplant patients. Transplantation 1985; 39:23-5.
65. de Villiers EM, Lavergne D, McLaren K, Benton EC. Prevailing papillomavirus types in non-melanoma carcinomas of the skin in renal allograft recipients. Int J Cancer 1997; 73:356-61.
66. Melbye M, Cote TR, Kessler L, Gail M, Biggar RJ. High incidence of anal cancer among AIDS patients. The AIDS/Cancer Working Group. Lancet 1994; 343:636-9.
67. Melbye M, Rabkin C, Frisch M, Biggar RJ. Changing patterns of anal cancer incidence in the United States, 1940-1989. Am J Epidemiol 1994; 139:772-80.
68. Frisch M, Biggar RJ, Goedert JJ. Human papillomavirus-associated cancers in patients with human immunodeficiency virus infection and acquired immunodeficiency syndrome. J Natl Cancer Inst 2000; 92:1500-10.
69. Frisch M, Fenger C, van den Brule AJ, et al. Variants of squamous cell carcinoma of the anal canal and perianal skin and their relation to human papillomaviruses. Cancer Res 1999; 59:753-7.
70. Langley CL, Benga-De E, Critchlow CW, et al. HIV-1, HIV-2, human papillomavirus infection and cervical neoplasia in high-risk African women. AIDS 1996; 10:413-7.
71. Massad LS, Riester KA, Anastos KM, et al. Prevalence and predictors of squamous cell abnormalities in Papanicolaou smears from women infected with HIV-1. Women's Interagency HIV Study Group. J Acquir Immune Defic Syndr 1999; 21:33-41.
72. Palefsky JM, Minkoff H, Kalish LA, et al. Cervicovaginal human papillomavirus infection in human immunodeficiency virus-1 (HIV)-positive and high-risk HIV-negative women. J Natl Cancer Inst 1999; 91:226-36.
73. Bonnez W, Kashima HK, Leventhal B, et al. Antibody response to human papillomavirus (HPV) type 11 in children with juvenile-onset recurrent respiratory papillomatosis (RRP). Virology 1992; 188:384-7.
74. Terry RM, Lewis FA, Griffiths S, Wells M, Bird CC. Demonstration of human papillomavirus types 6 and 11 in juvenile laryngeal papillomatosis by in-situ DNA hybridization. J Pathol 1987; 153:245-8.
75. Terry RM, Lewis FA, Robertson S, Blythe D, Wells M. Juvenile and adult laryngeal papillomata: classification by in-situ hybridization for human papillomavirus. Clin Otolaryngol 1989; 14:135-9.
76. Shah K, Kashima H, Polk BF, Shah F, Abbey H, Abramson A. Rarity of cesarean delivery in cases of juvenile-onset respiratory papillomatosis. Obstet Gynecol 1986; 68:795-9.
77. Kashima HK, Shah F, Lyles A, et al. A comparison of risk factors in juvenile-onset and adult-onset recurrent respiratory papillomatosis. Laryngoscope 1992; 102:9-13.
78. Armstrong LR, Derkay CS, Reeves WC. Initial results from the national registry for juvenile-onset recurrent respiratory papillomatosis. RRP Task Force. Arch Otolaryngol Head Neck Surg 1999; 125:743-8.
79. Armstrong LR, Preston EJ, Reichert M, et al. Incidence and prevalence of recurrent respiratory papillomatosis among children in Atlanta and Seattle. Clin Infect Dis 2000; 31:107-9.
80. Wikstrom A. Clinical and serological manifestations of genital human papillomavirus infection. Acta Derm Venereol Suppl 1995; 193:1-85.
81. Meisels A, Fortin R. Condylomatous lesions of the cervix and vagina. I. Cytologic patterns. Acta Cytol 1976; 20:505-9.
82. Meisels A, Fortin R, Roy M. Condylomatous lesions of the cervix. II. Cytologic, colposcopic and histopathologic study. Acta Cytol 1977; 21:379-90.
83. von Krogh G, Lacey CJ, Gross G, Barrasso R, Schneider A. European course on HPV associated pathology: guidelines for primary care physicians for the diagnosis and management of anogenital warts. Sex Transm Infect 2000; 76:162-8.
84. Wikstrom A, Hedblad MA, Johansson B, et al. The acetic acid test in evaluation of subclinical genital papillomavirus infection: a comparative study on penoscopy, histopathology, virology and scanning electron microscopy findings. Genitourin Med 1992; 68:90-9.
85. Lukehart SA, Holmes KK, eds. Syphilis [part 7, infectious diseases; sect. 9, spirochetal diseases]. In: Braunwald E, Fauci AS, Isselbacher KJ, et al., eds: Harrison's Online. McGraw-Hill, 1999. Available at: http://www.harrisonsonline.com/server-java/Arknoid/amed/harrisons/co_ chapters/ch172/ch172_p01.html. Accessed 1 February 2001.
86. Bolognia JL, Braverman IM, eds. Part 2: cardinal manifestations and presentation of diseases, section 9: alterations in the skin. 14th ed. McGraw-Hill, 1999.
87. Berger TG, ed. Common dermatoses. 40th ed. New York: Lange Medical Books/McGraw-Hill Health Professions Division, 2001.
88. Habif TP. Genital warts. In: Baxter S, ed. Clinical dermatology: a color guide to diagnosis and therapy. 3rd ed. St. Louis: Mosby, 1996.
89. Sober AJ, Koh HK, Tran NLT, Washington CV, eds. Melanoma and other skin cancers [part 6, oncology and hematology; section 1, neoplastic disorders]. In Braunwald E, Fauci AS, Isselbacher KJ, et al., eds: Harrison's Online. McGraw-Hill, 1999. Available at: http://www.harrisonsonline.com/server-java/Arknoid/amed/harrisons/co_ chapters/ch086/ch086_p01.html. Accessed 1 February 2001.
90. Ihm CW, Park SL, Sung SY, Lee IS. Bowenoid epidermotropic metastatic squamous cell carcinoma. J Cutan Pathol 1996; 23:479-84.
91. Collina G, Rossi E, Bettelli S, Cook MG, Cesinaro AM, Trentini GP. Detection of human papillomavirus in extragenital Bowen's disease using in situ hybridization and polymerase chain reaction. Am J Dermatopathol 1995; 17:236-41.
92. Ikenberg H, Gissmann L, Gross G, Grussendorf-Conen El, zur Hausen H. Human papillomavirus type-16-related DNA in genital Bowen's disease and in Bowenoid papulosis. Int J Cancer 1983; 32:563-5.
93. Wade TR, Kopf AW, Ackerman AB. Bowenoid papulosis of the genitalia. Arch Dermatol 1979; 115:306-8.
94. Lloyd KM. Multicentric pigmented Bowen's disease of the groin. Arch Dermatol 1970; 101:48-51.
95. Wade TR, Kopf AW, Ackerman AB. Bowenoid papulosis of the penis. Cancer 1978; 42:1890-903.
96. Reichman RC, ed. Table 190.1: correlation of human papillomavirus type with disease. In: Braunwald E, Fauci AS, Isselbacher KJ, et al: Harrisons Online. McGraw-Hill, 1999. Available at: http://www.harrisonsonline.com/server-java/Arknoid/amed/harrisons/co_ chapters/ch190/ch190_table01.html. Accessed 21 February 2001.
97. Salvatore P, Irina P, Amina V. The presence of HPV types 6/11, 16/18, 31/33/51 in Bowenoid papulosis demonstrated by DNA in situ hybridization. Int J STD AIDS 2000; 11:823-4.
98. Yoneta A, Yamashita T, Jin HY, Iwasawa A, Kondo S, Jimbow K. Development of squamous cell carcinoma by two high-risk human papillomaviruses (HPVs), a novel HPV-67 and HPV-31 from Bowenoid papulosis. Br J Dermatol 2000; 143:604-8.
99. Lehn H, Ernst TM, Sauer G. Transcription of episomal papillomavirus DNA in human condylomata acuminata and Buschke-Lowenstein tumours. J Gen Virol 1984; 65:2003-10.
100. Rubben A, Beaudenon S, Favre M, Schmitz W, Spelten B, Grussendorf-Conen EI. Rearrangements of the upstream regulatory region of human papillomavirus type 6 can be found in both Buschke-Lowenstein tumours and in condylomata acuminata. J Gen Virol 1992; 73:3147-53.
101. Chu QD, Vezeridis MP, Libbey NP, Wanebo HJ. Giant condyloma acuminatum (Buschke-Lowenstein tumor) of the anorectal and perianal regions: analysis of 42 cases. Dis Colon Rectum 1994; 37:950-7.
102. Maitland JE, Maw R. An audit of patients who have received imiquimod cream 5% for the treatment of anogenital warts. Int J STD AIDS 2000; 11:268-70.
103. Reynolds M, Fraser PA, Lacey CJ. Audits of the treatment of genital warts: closing the feedback loop. Int J STD AIDS 1996; 7:347-52.
104. Snoeck R, Van Ranst M, Andrei G, et al. Treatment of anogenital papillomavirus infections with an acyclic nucleoside phosphonate analogue [letter]. N Engl J Med 1995; 333:943-4.
105. Orlando G, Fasolo MM, Beretta R, et al. Intralesional or topical cidofovir (HPMPC, VISTIDE) for the treatment of recurrent genital warts in HIV-1-infected patients [letter]. AIDS 1999; 13:1978-80.
106. Schurmann D, Bergmann F, Temmesfeld-Wollbruck B, Grobusch MP, Suttorp N. Topical cidofovir is effective in treating extensive penile condylomata acuminata. AIDS 2000; 14:1075-6.
107. Stone KM, Becker TM, Hadgu A, Kraus SJ. Treatment of external genital warts: a randomised clinical trial comparing podophyllin, cryotherapy, and electrodesiccation. Genitourin Med 1990; 66:16-9.
108. Edwards L, Ferenczy A, Eron L, et al. Multicenter safety and efficacy trial evaluating three times per week application of 1% and 5% topical imiquimod for the treatment of genital/perianal warts [abstract]. In: Proceedings of the International Society for Antiviral Research, 8th International Conference on Antiviral Research (Santa Fe, NM). 1995.
109. Beutner KR, Tyring SK, Trofatter KF Jr, et al. Imiquimod, a patient-applied immune-response modifier for treatment of external genital warts. Antimicrob Agents Chemother 1998; 42:789-94.
110. Douglas JM Jr, Eron LJ, Judson FN, et al. A randomized trial of combination therapy with intralesional interferon � 2b and podophyllin versus podophyllin alone for the therapy of anogenital warts. J Infect Dis 1990; 162:52-9.
111. Godley MJ, Bradbeer CS, Gellan M, Thin RN. Cryotherapy compared with trichloroacetic acid in treating genital warts. Genitourin Med 1987; 63:390-2.
112. Ghosh AK. Cryosurgery of genital warts in cases in which podophyllin treatment failed or was contraindicated. Br J Vener Dis 1977; 53:49-53.
113. Wiley DJ, Beutner KR. Genital warts. Clin Evidence 2000; 3:764-74.
114. Strand A, Brinkeborn RM, Siboulet A. Topical treatment of genital warts in men, an open study of podophyllotoxin cream compared with solution. Genitourin Med 1995; 71:387-90.
115. Syed TA, Lundin S, Ahmad M. Topical 0.3% and 0.5% podophyllotoxin cream for self-treatment of molluscum contagiosum in males. A placebo-controlled, double-blind study. Dermatology 1994; 189:65-8.
116. Von Krogh G. Penile condylomata acuminata: an experimental model for evaluation of topical self-treatment with 0.5-1.0% ethanolic preparations of podophyllotoxin for three days. Sex Transm Dis 1981; 8:179-86.
117. Von Krogh G. Topical self-treatment of penile warts with 0.5% podophyllotoxin in ethanol for four or five days. Sex Transm Dis 1987; 14:135-40.
118. Von Krogh G, Hellberg D. Self-treatment using a 0.5% podophyllotoxin cream of external genital condylomata acuminata in women. A placebo-controlled, double-blind study. Sex Transm Dis 1992; 19:170-4.
119. Von Krogh G, Szpak E, Andersson M, Bergelin I. Self-treatment using 0.25%-0.50% podophyllotoxin-ethanol solutions against penile condylomata acuminata: a placebo-controlled comparative study. Genitourin Med 1994; 70:105-9.
120. Beutner KR, Conant MA, Friedman-Kien AE, et al. Patient-applied podofilox for treatment of genital warts. Lancet 1989; 1:831-4.
121. Petersen CS, Weismann K. Quercetin and kaempherol: an argument against the use of podophyllin? Genitourin Med 1995; 71:92-3.
122. Kirby P, Dunne King D, Corey L. Double-blind randomized clinical trial of self-administered podofilox solution versus vehicle in the treatment of genital warts. Am J Med 1990; 88:465-9.
123. Tyring S, Edwards L, Cherry LK, et al. Safety and efficacy of 0.5% podofilox gel in the treatment of anogenital warts. Arch Dermatol 1998; 134:33-8.
124. Edwards A, Atma-Ram A, Thin RN. Podophyllotoxin 0.5% v podophyllin 20% to treat penile warts. Genitourin Med 1988; 64:263-5.
125. Syed TA, Khayyami M, Kriz D, et al. Management of genital warts in women with human leukocyte interferon-alpha vs. podophyllotoxin in cream: a placebo-controlled, double-blind, comparative study. J Mol Med 1995; 73:255-8.
126. Edwards L, Ferenczy A, Eron L, et al. Self-administered topical 5% imiquimod cream for external anogenital warts. Arch Dermatol 1998; 134:25-30.
127. Fife KH, Ferenczy A, Douglas JM Jr, Brown DR, Smith M, Owens ML. Treatment of external genital warts in men using 5% imiquimod cream applied three times a week, once daily, twice daily, or three times a day. Sex Transm Dis 2001; 28:226-31.
128. Abdullah AN, Walzman M, Wade A. Treatment of external genital warts comparing cryotherapy (liquid nitrogen) and trichloroacetic acid. Sex Transm Dis 1993; 20:344-5.
129. Handley JM, Horner T, Maw RD, Lawther H, Dinsmore WW. Subcutaneous interferon alpha 2a combined with cryotherapy vs cryotherapy alone in the treatment of primary anogenital warts: a randomised observer blind placebo controlled study. Genitourin Med 1991; 67:297-302.
130. Bergman A, Bhatia NN, Broen EM. Cryotherapy for treatment of genital condylomata during pregnancy. J Reprod Med 1984; 29:432-5.
131. Bergman A, Bhatia NN, Broen EM. Cryotherapy for treatment of genital condylomata during pregnancy. JAMA 1983; 250:336.
132. Gabriel G, Thin RN. Treatment of anogenital warts. Comparison of trichloracetic acid and podophyllin versus podophyllin alone. Br J Vener Dis 1983; 59:124-6.
133. Hellberg D, Svarrer T, Nilsson S, Valentin J. Self-treatment of female external genital warts with 0.5% podophyllotoxin cream (Condyline) vs weekly applications of 20% podophyllin solution. Int J STD AIDS 1995; 6:257-61.
134. Kinghorn GR, McMillan A, Mulcahy F, Drake S, Lacey C, Bingham JS. An open, comparative, study of the efficacy of 0.5% podophyllotoxin lotion and 25% podophyllotoxin solution in the treatment of condylomata acuminata in males and females. Int J STD AIDS 1993; 4:194-9.
135. Lassus A, Haukka K, Forsstrom S. Podophyllotoxin for treatment of genital warts in males: a comparison with conventional podophyllin therapy. Eur J Sex Transm Dis 1984; 2:31-3.
136. Benedetti Panici P, Scambia G, Baiocchi G, Perrone L, Pintus C, Mancuso S. Randomized clinical trial comparing systemic interferon with diathermocoagulation in primary multiple and widespread anogenital condyloma. Obstet Gynecol 1989; 74:393-7.
137. Simmons PD, Langlet F, Thin RN. Cryotherapy versus electrocautery in the treatment of genital warts. Br J Vener Dis 1981; 57:273-4.
138. Jensen SL. Comparison of podophyllin application with simple surgical excision in clearance and recurrence of perianal condylomata acuminata. Lancet 1985; 2:1146-8.
139. Khawaja HT. Podophyllin versus scissor excision in the treatment of perianal condylomata acuminata: a prospective study. Br J Surg 1989; 76:1067-8.
140. Duus BR, Philipsen T, Christensen JD, Lundvall F, Sondergaard J. Refractory condylomata acuminata: a controlled clinical trial of carbon dioxide laser versus conventional surgical treatment. Genitourin Med 1985; 61:59-61.
141. Reid R, Greenberg MD, Pizzuti DJ, Omoto KH, Rutledge LH, Soo W. Superficial laser vulvectomy. V. Surgical debulking is enhanced by adjuvant systemic interferon. Am J Obstet Gynecol 1992; 166:815-20.
142. Petersen C, Bjerring P, Larson J, et al. Systemic interferon alpha-2b increases the cure rate in laser treated patients with multiple persistent genital warts: a placebo-controlled study. Genitourin Med 1991; 67:99-102.
143. Keay S, Teng N, Eisenberg M, Story B, Sellers PW, Merigan TC. Topical interferon for treating condyloma acuminata in women. J Infect Dis 1988; 158:934-9.
144. Gross G, Rogozinski T, Schofer H, et al. Recombinant interferon beta gel as an adjuvant in the treatment of recurrent genital warts: results of a placebo-controlled double-blind study in 120 patients. Dermatology 1998; 196:330-4.
145. Friedman-Kien AE, Eron LJ, Conant M, et al. Natural interferon alfa for treatment of condylomata acuminata. JAMA 1988; 259:533-8.
146. Eron LJ, Judson F, Tucker S, et al. Interferon therapy for condylomata acuminata. N Engl J Med 1986; 315:1059-64.
147. Friedman-Kien A. Management of condylomata acuminata with Alferon N injection, interferon alfa-n3 (human leukocyte derived). Am J Obstet Gynecol 1995; 172:1359-68.
148. Monsonego J, Cessot G, Ince SE, Galazka AR, Abdul-Ahad AK. Randomised double-blind trial of recombinant interferon-beta for condyloma acuminatum. Genitourin Med 1996; 72:111-4.
149. Reichman RC, Oakes D, Bonnez W, et al. Treatment of condyloma acuminatum with three different, interferons administered intralesionally: a double-blind, placebo-controlled trial. Ann Intern Med 1988; 108:675-9.
150. Scott GM, Csonka GW. Effect of injections of small doses of human fibroblast interferon into genital warts: a pilot study. Br J Vener Dis 1979; 55:442-5.
151. Vance JC, Bart BJ, Hansen RC, et al. Intralesional recombinant alpha-2 interferon for the treatment of patients with condyloma acuminatum or verruca plantaris. Arch Dermatol 1986; 122:272-7.
152. Welander CE, Homesley HD, Smiles KA, Peets EA. Intralesional interferon alfa-2b for the treatment of genital warts. Am J Obstet Gynecol 1990; 162:348-54.
153. Bornstein J, Pascal B, Zarfati D, Goldshmid N, Abramovici H. Recombinant human interferon-beta for condylomata acuminata: a randomized, double-blind, placebo-controlled study of intralesional therapy. Int J STD AIDS 1997; 8:614-21.
154. Reichman R, Oakes D, Bonnez W, et al. Treatment of condyloma acuminatum with three different interferon-preparations administered parenterally: a double-blind, placebo-controlled trial. J Infect Dis 1990; 162:1270-6.
155. Gall SA, Constantine L, Koukol D. Therapy of persistent human papillomavirus disease with two different interferon species. Am J Obstet Gynecol 1991; 164:130-4.
156. Olmos L, Vilata J, Rodriguez Pichardo A, Lloret A, Ojeda A, Calderon MD. Double-blind, randomized clinical trial on the effect of interferon-beta in the treatment of condylomata acuminata. Int J STD AIDS 1994; 5:182-5.
157. Bonnez W, Oakes D, Bailey-Farchione A, et al. A randomized, doubleblind trial of parenteral low dose versus high dose interferon-beta in combination with cryotherapy for treatment of condyloma acuminatum. Antiviral Res 1997; 35:41-52.
158. Krebs H. Treatment of extensive vulvar condylomata acuminata with topical 5-fluorouracil. South Med J 1990;83:761-4.
159. Haye KR. Letter: Treatment of condyloma acuminata with 5 per cent. 5-fluorouracil (5-FU) cream. Br J Vener Dis 1974; 50:466.
160. Shah KV, Stern WF, Shah FK, Bishai D, Kashima HK. Risk factors for juvenile onset recurrent respiratory papillomatosis. Pediatr Infect Dis J 1998; 17:372-6.
161. Bishai D, Kashima H, Shah K. The cost of juvenile-onset recurrent respiratory papillomatosis. Arch Otolaryngol Head Neck Surg 2000; 126:935-9.
162. Von Krogh G. The beneficial effect of 1% 5-fluorouracil in 70% ethanol on therapeutically refractory condylomas in the preputial cavity. Sex Transm Dis 1978; 5:137-40.
163. Harrison CJ, Jenski L, Voychehovski T, Bernstein DI. Modification of immunological responses and clinical disease during topical R-837 treatment of genital HSV-2 infection. Antiviral Res 1988; 10:209-23 [erratum Antiviral Res 1989; 11:215].
164. Sidky YA, Borden EC, Weeks CE, Reiter MJ, Hatcher JF, Bryan GT. Inhibition of murine tumor growth by an interferon-inducing imidazoquinolinamine. Cancer Res 1992;52:3528-33.
165. Beutner KR, Spruance SL, Hougham AJ, Fox TL, Owens ML, Douglas JM Jr. Treatment of genital warts with an immune-response modifier (imiquimod). J Am Acad Dermatol 1998; 38:230-9.
166. Cassidy DE, Drewry J, Fanning JP. Podophyllum toxicity: a report of a fatal case and a review of the literature. J Toxicol Clin Toxicol 1982; 19:35-44.
167. Bernstein DI, Miller RL, Harrison CJ. Effects of therapy with an immunomodulator (imiquimod, R-837) alone and with acyclovir on genital HSV-2 infection in guinea-pigs when begun after lesion development. Antiviral Res 1993; 20:45-55.
168. Tyring SK, Arany I, Stanley MA, et al. A randomized, controlled, molecular study of condylomata acuminata clearance during treatment with imiquimod. J Infect Dis 1998; 178:551-5.
169. Leslie KO, Shitamoto B. The bone marrow in systemic podophyllin toxicity. Am J Clin Pathol 1982; 77:478-80.
170. Filley CM, Graff-Richard NR, Lacy JR, Heitner MA, Earnest MP. Neurologic manifestations of podophyllin toxicity. Neurology 1982; 32:308-11.
171. Boillot A, Cordier A, Guerault E, et al. A rare case of severe toxic peripheral neuropathy: poisoning by podophyllin. Apropos of 1 case (author's transl). J Toxicol Clin Exp 1989; 9:409-12.
172. Gorin F, Kindall D, Seyal M. Dorsal radiculopathy resulting from podophyllin toxicity. Neurology 1989; 39:607-8.
173. Yang CM, Deng JF, Chen CF, Chang LW. Experimental podophyllotoxin (bajiaolian) poisoning: III. Biochemical bases for toxic effects. Biomed Environ Sci 1994; 7:259-65.
174. Kao WF, Hung DZ, Tsai WJ, Lin KP, Deng JF. Podophyllotoxin
175. Tomczak RL, Hake DH. Near fatal systemic toxicity from local injection of podophyllin for pedal verrucae treatment. J Foot Surg 1992; 31:36-42.
176. Chan YW. Magnetic resonance imaging in toxic encephalopathy due to podophyllin poisoning. Neuroradiology 1991; 33:372-3.
177. Conard PF, Hanna N, Rosenblum M, Gross JB. Delayed recognition of podophyllum toxicity in a patient receiving epidural morphine. Anesth Analg 1990; 71:191-3.
178. Oliveira AS, Calia LC, Kiyomoto BH, Povoa EF, Schmidt B, Gabbai AA. Acute necrotizing myopathy and podophyllin toxicity: report of a fatal case. Arq Neuropsiquiatr 1996; 54:288-92.
179. American Conference of Governmental Industrial Hygienists (ACGIH). Documentation of the threshold limit values and biological exposure indices. Cincinnati: ACGIH, 1991.
180. Schwartz DB, Greenberg MD, Daoud Y, Reid R. Genital condylomas in pregnancy: use of trichloroacetic acid and laser therapy. Am J Obstet Gynecol 1988; 158:1407-16.
181. Miller RD. Local anesthetics. In: Miller RD, ed. Anesthesia. 5th ed. Philadelphia: Churchill-Livingstone, Harcourt Brace & Company, 2000:2877.
182. Schoenfeld A, Ziv E, Levavi H, Samra Z, Ovadia J. Laser versus loop electrosurgical excision in vulvar condyloma for eradication of subclinical reservoir demonstrated by assay for 2�5� oligosynthetase human papillomavirus. Gynecol Obstet Invest 1995; 40:46-51.
183. Syed TA, Ahmadpour OA. Human leukocyte derived interferon -alpha in a hydrophilic gel for the treatment of intravaginal warts in women: a placebo-controlled, double-blind study. Int J STD AIDS 1998; 9:769-72.
184. Syed TA, Ahmadpour OA, Ahmad SA, Ahmad SH. Human leukocyte interferon-alpha in a hydrophilic cream versus in a gel for the treatment of genital herpes in males: a placebo-controlled, double-blind, comparative study. J Dermatol 1997; 24:564-8.
185. Shah RM, MacKay RA. Teratological evaluation of 5-fluorouracil and 5-bromo-2-deoxyuridine on hamster fetuses. J Embryol Exp Morphol 1978; 43:47-54.
186. Van Le L, Pizzuti DJ, Greenberg M, Reid R. Accidental use of lowdose 5-fluorouracil in pregnancy. J Reprod Med 1991; 36:872-4.
187. Dreicer R, Love RR. High total dose 5-fluorouracil treatment during pregnancy. Wisc Med J 1991; 90:582-3.
188. Comprehensive index: cidofovir. In: David Nissen P, ed. 2002 Mosby's drug consult. St. Louis: Mosby, 2002. Available at: http://home .mdconsult.com/das/drug/view/14956640. Accessed 1 December 2001.
189. Marrazzo JM, Koutsky LA, Stine KL, et al. Genital human papillomavirus infection in women who have sex with women. J Infect Dis 1998; 178:1604-9.
190. Marrazzo JM, Stine K, Koutsky LA. Genital human papillomavirus infection in women who have sex with women: a review. Am J Obstet Gynecol 2000; 183:770-4.
191. Manos MM, Kinney WK, Hurley LB, et al. Identifying women with cervical neoplasia: using human papillomavirus DNA testing for equivocal Papanicolaou results. JAMA 1999; 281:1605-10.
192. Solomon D, Schiffman M, Tarone R. Comparison of three management strategies for patients with atypical squamous cells of undetermined significance: baseline results from a randomized trial. J Natl Cancer Inst 2001; 93:293-9.
193. Dvorak KA, Finnemore M, Maksem JA. Histology correlation with atypical squamous cells of undetermined significance (ASCUS) and low-grade squamous intraepithelial lesion (LSIL) cytology diagnoses: an argument to ensure ASCUS follow-up that is as aggressive as that for LSIL. Diagn Cytopathol 1999; 21:292-5.
194. Human papillomavirus testing for triage of women with cytologic evidence of low-grade squamous intraepithelial lesions: baseline data from a randomized trial. The Atypical Squamous Cells of Undetermined Significance/Low-Grade Squamous Intraepithelial Lesions Triage Study (ALTS) Group. J Natl Cancer Inst 2000; 92:397-402.
195. Hall S, Lorincz A, Shah F, et al. Human papillomavirus DNA detection in cervical specimens by hybrid capture: correlation with cytologic and histologic diagnoses of squamous intraepithelial lesions of the cervix. Gynecol Oncol 1996; 62:353-9.
196. Cope JU, Hildesheim A, Schiffman MH, et al. Comparison of the hybrid capture tube test and PCR for detection of human papillomavirus DNA in cervical specimens. J Clin Microbiol 1997; 35:2262-5.
197. Frisch M, Glimelius B, van den Brule AJ, et al. Sexually transmitted infection as a cause of anal cancer. N Engl J Med 1997; 337:1350-8.
198. Melbye M, Frisch M. The role of human papillomaviruses in anogenital cancers. Semin Cancer Biol 1998; 8:307-13.
199. Melbye M, Smith E, Wohlfahrt J, et al. Anal and cervical abnormality in women - prediction by human papillomavirus tests. Int J Cancer 1996; 68:559-64.
200. Palefsky J. Human papillomavirus-associated malignancies in HIV-positive men and women. Curr Opin Oncol 1995; 7:437-41.
201. Palefsky JM. Human papillomavirus-associated anogenital neoplasia and other solid tumors in human immunodeficiency virus-infected individuals. Curr Opin Oncol 1991; 3:881-5.
202. Palefsky JM. Anal human papillomavirus infection and anal cancer in HIV-positive individuals: an emerging problem [editorial]. AIDS 1994; 8:283-95.
203. Palefsky JM. Cutaneous and genital HPV-associated lesions in HIV-infected patients. Clin Dermatol 1997; 15:439-47.
204. Palefsky JM. Human papillomavirus infection and anogenital neoplasia in human immunodeficiency virus-positive men and women. J Natl Cancer Inst Monogr 1998; 23:15-20.
205. Palefsky JM. Anal squamous intraepithelial lesions: relation to HIV and human papillomavirus infection. J Acquir Immune Defic Syndr 1999; 21(Suppl 1):S42-8.
206. Palefsky JM, Holly EA, Ralston ML, Arthur SP, Hogeboom CJ, Darragh TM. Anal cytological abnormalities and anal HPV infection in men with Centers for Disease Control group IV HIV disease. Genitourin Med 1997; 73:174-80.
207. Palefsky JM, Holly EA, Ralston ML, et al. Anal squamous intraepithelial lesions in HIV-positive and HIV-negative homosexual and bisexual men: prevalence and risk factors. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 17:320-6.
208. Palefsky JM, Holly EA, Ralston ML, Jay N. Prevalence and risk factors for human papillomavirus infection of the anal canal in human immunodeficiency virus (HIV)-positive and HIV-negative homosexual men. J Infect Dis 1998; 177:361-7.
209. Palefsky JM, Holly EA, Ralston ML, Jay N, Berry JM, Darragh TM. High incidence of anal high-grade squamous intra-epithelial lesions among HIV-positive and HIV-negative homosexual and bisexual men. AIDS 1998; 12:495-503.
210. Goldie SJ, Kuntz KM, Weinstein MC, Freedberg KA, Palefsky JM. Cost-effectiveness of screening for anal squamous intraepithelial lesions and anal cancer in human immunodeficiency virus-negative homosexual and bisexual men. Am J Med 2000; 108:634-41.
211. Goldie SJ, Kuntz KM, Weinstein MC, Freedberg KA, Welton ML, Palefsky JM. The clinical effectiveness and cost-effectiveness of screening for anal squamous intraepithelial lesions in homosexual and bisexual HIV-positive men. JAMA 1999; 281:1822-9.
212. Volberding P. Looking behind: time for anal cancer screening. Am J Med 2000; 108:674-5.
213. Critchlow CW, Surawicz CM, Holmes KK, et al. Prospective study of high grade anal squamous intraepithelial neoplasia in a cohort of homosexual men: influence of HIV infection, immunosuppression and human papillomavirus infection. AIDS 1995; 9:1255-62.
214. Palefsky JM, Holly EA, Gonzales J, Lamborn K, Hollander H. Natural history of anal cytologic abnormalities and papillomavirus infection among homosexual men with group IV HIV disease. J Acquir Immune Defic Syndr 1992; 5:1258-65.
215. Darragh TM, Jay N, Tupkelewicz BA, Hogeboom CJ, Holly EA, Palefsky JM. Comparison of conventional cytologic smears and ThinPrep preparations from the anal canal. Acta Cytol 1997; 41:1167-70.
216. Palefsky JM, Holly EA, Hogeboom CJ, Berry JM, Jay N, Darragh TM. Anal cytology as a screening tool for anal squamous intraepithelial lesions. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 14:415-22.
217. Adam MB, Auerbach JD, Buehler JW, et al. Workshop summary: scientific evidence on condom effectiveness for sexually transmitted disease (STD) prevention. Herndon, VA: National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services. Available at http://www.niaid.nih.gov/dmid/stds/condomreport.pdf; accessed 21 February 2001.
218. Wen LM, Estcourt CS, Simpson JM, Mindel A. Risk factors for the acquisition of genital warts: are condoms protective? Sex Transm Infect 1999; 75:312-6.
219. Ferenczy A, Mitao M, Nagai N, Silverstein SJ, Crum CP. Latent papillomavirus and recurring genital warts. N Engl J Med 1985; 313:784-8.
220. Cason J, Kaye JN, Best JM, Raju KS. Cancer associated human papillomaviruses: perinatal transmission and persistence [letter]. Br J Obstet Gynaecol 1995; 102:583.
221. Kaye JN, Starkey WG, Kell B, et al. Human papillomavirus type 16 in infants: use of DNA sequence analyses to determine the source of infection. J Gen Virol 1996; 77:1139-43.
222. Pakarian F, Kaye J, Cason J, et al. Cancer associated human papillomaviruses: perinatal transmission and persistence. Br J Obstet Gynaecol 1994; 101:514-7.
223. Tseng CJ, Liang CC, Soong YK, Pao CC. Perinatal transmission of human papillomavirus in infants: relationship between infection rate and mode of delivery. Obstet Gynecol 1998; 91:92-6.
224. Watts DH, Koutsky LA, Holmes KK, et al. Low risk of perinatal transmission of human papillomavirus: results from a prospective cohort study. Am J Obstet Gynecol 1998; 178:365-73.
225. Sedlacek TV, Lindheim S, Eder C, et al. Mechanism for human papillomavirus transmission at birth. Am J Obstet Gynecol 1989; 161:55-9.
226. Smith EM, Johnson SR, Cripe TP, Pignatari S, Turek L. Perinatal vertical transmission of human papillomavirus and subsequent development of respiratory tract papillomatosis. Ann Otol Rhinol Laryngol 1991; 100:479-83.
227. Smith EM, Johnson SR, Jiang D, et al. The association between pregnancy and human papilloma virus prevalence. Cancer Detect Prevent 1991; 15:397-402.
228. Armbruster-Moraes E, Ioshimoto LM, Leao E, Zugaib M. Detection of human papillomavirus deoxyribonucleic acid sequences in amniotic fluid during different periods of pregnancy [letter]. Am J Obstet Gynecol 1993; 169:1074.
229. Fife KH, Katz BP, Brizendine EJ, Brown DR. Cervical human papillomavirus deoxyribonucleic acid persists throughout pregnancy and decreases in the postpartum period. Am J Obstet Gynecol 1999; 180:1110-4.
230. Fife KH, Rogers RE, Zwickl BW. Symptomatic and asymptomatic cervical infections with human papillomavirus during pregnancy. J Infect Dis 1987; 156:904-11.
231. Rando RF, Lindheim S, Hasty L, Sedlacek TV, Woodland M, Eder C. Increased frequency of detection of human papillomavirus deoxyribonucleic acid in exfoliated cervical cells during pregnancy. Am J Obstet Gynecol 1989; 161:50-5.
232. Ip EW, Collins RJ, Cheung AN, Srivastava G. Prevalence of low and high risk human papillomavirus types in cervical cells from Hong Kong pregnant Chinese using filter in situ hybridization. Arch Gynecol Obstet 1991; 249:1-7.
233. Kashima HK, Shah K. Recurrent respiratory papillomatosis. Clinical overview and management principles. Obstet Gynecol Clin North Am 1987; 14:581-8.
234. van Ham MA, van Dongen PW, Mulder J. Maternal consequences of caesarean section. A retrospective study of intra-operative and postoperative maternal complications of caesarean section during a 10-year period. Eur J Obstet Gynecol Reprod Biol 1997; 74:1-6.